WO2020139237A3 - Formulation de comprimé bicouche d'atorvastatine calcique et d'ézétimibe - Google Patents

Formulation de comprimé bicouche d'atorvastatine calcique et d'ézétimibe Download PDF

Info

Publication number
WO2020139237A3
WO2020139237A3 PCT/TR2019/051006 TR2019051006W WO2020139237A3 WO 2020139237 A3 WO2020139237 A3 WO 2020139237A3 TR 2019051006 W TR2019051006 W TR 2019051006W WO 2020139237 A3 WO2020139237 A3 WO 2020139237A3
Authority
WO
WIPO (PCT)
Prior art keywords
ezetimibe
tablet formulation
atorvastatin calcium
bilayer tablet
present
Prior art date
Application number
PCT/TR2019/051006
Other languages
English (en)
Other versions
WO2020139237A2 (fr
Inventor
Selin KOKSAL UZUN
Ediz Yildirim
Ali Turkyilmaz
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2020139237A2 publication Critical patent/WO2020139237A2/fr
Publication of WO2020139237A3 publication Critical patent/WO2020139237A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation de comprimé pharmaceutique bicouche comprenant de l'atorvastatine calcique et de l'ézétimibe. En outre, la présente invention concerne un procédé qui élimine les inconvénients des agents actifs.
PCT/TR2019/051006 2018-12-25 2019-11-28 Formulation de comprimé bicouche d'atorvastatine calcique et d'ézétimibe WO2020139237A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/20324A TR201820324A2 (en) 2018-12-25 2018-12-25 ATORVASTATIN CALCIUM AND EZETİMİBİN PHARMACEUTICAL DOUBLE LAYER TABLET FORMULATION
TR2018/20324 2018-12-25

Publications (2)

Publication Number Publication Date
WO2020139237A2 WO2020139237A2 (fr) 2020-07-02
WO2020139237A3 true WO2020139237A3 (fr) 2020-07-30

Family

ID=71128823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/051006 WO2020139237A2 (fr) 2018-12-25 2019-11-28 Formulation de comprimé bicouche d'atorvastatine calcique et d'ézétimibe

Country Status (2)

Country Link
TR (1) TR201820324A2 (fr)
WO (1) WO2020139237A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188338A1 (fr) 2020-07-27 2023-06-07 KRKA, d.d., Novo mesto Comprimé bicouche comprenant de l'ézétimibe et de l'atorvastatine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002422A2 (fr) * 2009-07-02 2011-01-06 Bilgic Mahmut Formulation pharmaceutique améliorant la solubilité
WO2013166114A1 (fr) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Formulation de comprimé oral constituée d'une combinaison fixe d'atorvastatine et d'ézétimibe
EP3360541A1 (fr) * 2017-02-13 2018-08-15 Sanovel Ilac Sanayi ve Ticaret A.S. Composition de comprimés bicouche pharmaceutiques de calcium d'atorvastatine et d'ézétimibe

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002422A2 (fr) * 2009-07-02 2011-01-06 Bilgic Mahmut Formulation pharmaceutique améliorant la solubilité
WO2013166114A1 (fr) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Formulation de comprimé oral constituée d'une combinaison fixe d'atorvastatine et d'ézétimibe
EP3360541A1 (fr) * 2017-02-13 2018-08-15 Sanovel Ilac Sanayi ve Ticaret A.S. Composition de comprimés bicouche pharmaceutiques de calcium d'atorvastatine et d'ézétimibe

Also Published As

Publication number Publication date
TR201820324A2 (en) 2020-07-21
WO2020139237A2 (fr) 2020-07-02

Similar Documents

Publication Publication Date Title
SA519401336B1 (ar) تركيبة صيدلية
WO2016064082A3 (fr) Nouveau dérivé aminoalkyle benzothiazépine et son utilisation
WO2017191130A3 (fr) Inhibiteurs d'arginase et leurs applications thérapeutiques
EP4233846A3 (fr) Formulations pharmaceutiques
WO2018165404A8 (fr) Formulations pharmaceutiques de phloroglucinol et de triméthylphloroglucinol
WO2019186284A3 (fr) Palet de cannabis à dose définie
WO2018183631A8 (fr) Nouvelles formulations pharmaceutiques contenant de l'indirubine et des dérivés de celui-ci et procédés de fabrication et d'utilisation de celles-ci
WO2018106108A8 (fr) Composition pharmaceutique topique contenant de la phénytoïne et un (co-)analgésique pour le traitement de la douleur chronique
EP3909597A4 (fr) Composition pharmaceutique permettant de prévenir ou de traiter le cancer contenant un oligopeptide en tant que principe actif
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
WO2020139237A3 (fr) Formulation de comprimé bicouche d'atorvastatine calcique et d'ézétimibe
WO2019240699A3 (fr) Formulations de comprimés comprenant de la metformine et de la sitagliptine traitées par extrusion à chaud
WO2016006974A3 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
WO2016006975A3 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
EP3599892A4 (fr) Produits de gel à mâcher pour principes actifs pharmaceutiques
EP3876991A4 (fr) Nouveaux principes actifs pharmaceutiques amorphes comprenant du carbonate de magnésium mésoporeux sensiblement amorphe
EP3749289A4 (fr) Produit multiparticulaire comprenant des substances actives pharmaceutiques ou probiotiques
WO2019151964A3 (fr) Formulations de saxagliptine à délitement buccal
WO2019059857A3 (fr) Dispositif pour combiner plusieurs médicaments
WO2020018053A3 (fr) Comprimé comprenant du dasatinib
WO2018069805A3 (fr) Procédé de préparation d'une composition liquide de l-thyroxine à usage oral
EP3626703A4 (fr) Nouveau composé et composition pharmaceutique comprenant celui-ci en tant que principe actif
WO2019059868A3 (fr) Combinaisons pharmaceutiques de ténofovir, d'emtricitabine et d'éfavirenz
WO2020190900A8 (fr) Formulations pharmaceutiques à base d'abiratérone et d'oligomère cyclique et procédés de formation et d'administration de celles-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19901696

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19901696

Country of ref document: EP

Kind code of ref document: A2